Mebeverine

Generic Name: Mebeverine

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₅NO_₅

CAS Number: 3625-06-7

Unique Ingredient Identifier: 7F80CC3NNV

Overview

Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

Indication

治疗由肠易激综合症（IBS）引起的腹痛痉挛，肠功能紊乱和肠部不适，治疗由于器质性疾病继发引起的肠痉挛。

Associated Conditions

Abdominal Pain
Abdominal Spasms
Abnormal Bowel Movement Such as Constipation, Diarrhea, Abdominal Pain
Irritable Bowel Syndrome (IBS)
Bowel discomfort

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea	2023/05/22	NCT05867550	Phase 4	Completed	Bahria University
Ebastine Versus Mebeverine in IBS Patients	2023/04/18	NCT05815602	Phase 3	Recruiting	Guy Boeckxstaens
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders	2022/01/03	NCT05175131	Phase 3	Completed	Abbott
Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute	2020/11/19	NCT04635566	Not Applicable	Completed	Mansoura University
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome	2020/01/03	NCT04217733	Phase 3	Recruiting	Tanta University
Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm	2014/10/09	NCT02260154	N/A	Completed	Abbott
Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)	2009/07/08	NCT00934973	Phase 4	Completed	Hazel Everitt

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
DUSPATALIN RETARD CAPSULE 200 mg	ABBOTT BIOLOGICALS B.V., Mylan Laboratories SAS	SIN07666P	CAPSULE	200 mg	3/10/1994
MEBETIN TABLET 135 mg	SAM CHUN DANG PHARM CO LTD	SIN09873P	TABLET, SUGAR COATED	135 mg	7/9/1998

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
DUSPATALIN 135 mg COMPRIMIDOS RECUBIERTOS	Viatris Healthcare Limited	53900	COMPRIMIDO RECUBIERTO	Medicamento Sujeto A Prescripción Médica	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

No news found

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.